First Houston Capital’s Novo Nordisk NVO Stock Holding History

First Houston Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$335K	Buy	+15,600	New	+$315K	0.34%	62

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

First Houston Capital's NVO Position: Q2 2017 in Review

First Houston Capital opened a new position in Novo Nordisk (NVO) in Q2 2017: 15,600 shares worth $335K. The stake represents 0.34% of the portfolio and ranks #62 among its holdings.

484 funds tracked by Wall St. Rank hold NVO as of Q2 2017.

First Houston Capital held 15,600 shares of Novo Nordisk worth $335K as of Q2 2017.
Novo Nordisk was a new First Houston Capital position in Q2 2017.
Novo Nordisk made up 0.34% of First Houston Capital's portfolio in Q2 2017, its #62 holding.
484 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2017.

Based on First Houston Capital's 13F filing for Q2 2017, filed 7 Aug 2017.